Li Jia-Jia, Wu Yan-Ping, Zhang Meng-Meng, Wang Meng, Zhang Ping-Ping, Liu Lin
Department of Hematology, The First Affiliated Hospital of Bengbu Medical College, Bengbu 233003, Anhui Province, China.
Department of Hematology, The First Affiliated Hospital of Bengbu Medical College, Bengbu 233003, Anhui Province, China.E-mail:
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024 Apr;32(2):376-381. doi: 10.19746/j.cnki.issn.1009-2137.2024.02.008.
To detect the expression of RNA methyltransferase 14() in bone marrow of patients with newly diagnosed acute myeloid leukemia (AML), and to investigate the clinical and prognostic significance of expression in newly diagnosed AML.
Bone marrow samples were collected from 100 patients with newly diagnosed AML as observation group and 60 patients with iron deficiency anemia AML as control group. And collected the clinical data of the AML patients. Real-time quantitative PCR (qRT-PCR) was used to detect the expression level of in AML and IDA patients. The relationship between the expression level of and clinicopathological features, prognosis was analyzed. Kaplan-Meier curves were used to analyze the effect of on overall survival (OS) in AML patients. Cox risk regression model was used to analyze the prognostic factors affecting in patients with AML.
Compared with the control group, the expression of was significantly increased in AML patients ( < 0.05). Compared with the low-expression group, patients in the high-expression group had advanced age, high bone marrow cell number, poor efficacyand poor prognosis( < 0.05). The overall survival time of patients with the high-expression group was significantly shorter than that of the low-expression group ( < 0.05). The high expression of was an independent risk factor for poor prognosis in AML.
is significantly overexpressed in AML patients, and its correlated with poor clinicopathological features and poor prognosis. It can be used as a prognostic marker and potential therapeutie target for AML patients.
检测RNA甲基转移酶14（）在新诊断急性髓系白血病（AML）患者骨髓中的表达情况，探讨其表达在新诊断AML中的临床及预后意义。
收集100例新诊断AML患者的骨髓样本作为观察组，60例缺铁性贫血患者作为对照组。收集AML患者的临床资料。采用实时定量PCR（qRT-PCR）检测AML患者和IDA患者中 的表达水平。分析 表达水平与临床病理特征、预后的关系。采用Kaplan-Meier曲线分析 对AML患者总生存期（OS）的影响。采用Cox风险回归模型分析影响AML患者预后的因素。
与对照组相比，AML患者中 的表达显著升高（<0.05）。与 低表达组相比， 高表达组患者年龄较大、骨髓细胞数高、疗效差、预后差（<0.05）。 高表达组患者的总生存时间明显短于低表达组（<0.05）。 的高表达是AML患者预后不良的独立危险因素。
在AML患者中显著过表达，且与不良临床病理特征和预后相关。它可作为AML患者的预后标志物和潜在治疗靶点。
Zotero 插件